✓ Translated by DotMD AI Clinical Council Source: Expert opinion on pharmacotherapy • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #36932818 ↗

Phase III Randomized Trial: VV116 as a potential treatment for COVID-19

Original Paper Title: “VV116 as a potential treatment for COVID-19”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Among study subjects, VV116 was found to be noninferior to Paxlovid with respect to the time to sustained clinical recovery and with fewer safety concerns. This manuscript examines what is known about VV116 and explores how this novel treatment option may be used in the future to address the ongoing SARS-CoV-2 pandemic.
  • Study Design & Sample: Phase III Randomized Trial published in Expert opinion on pharmacotherapy (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Expert opinion on pharmacotherapy (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: VV116 is a chemically-modified version of the antiviral remdesivir with oral bioavailability and potent activity against SARS-CoV-2. Key clinical takeaway: Among study subjects, VV116 was found to be noninferior to Paxlovid with respect to the time to sustained clinical recovery and with fewer safety concerns. This manuscript examines what is known about VV116 and explores how this novel treatment option may be used in the future to address the ongoing SARS-CoV-2 pandemic.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Expert opinion on pharmacotherapy, 2023-04-15; Phase III Randomized Trial; Rigor 82/100): Among study subjects, VV116 was found to be noninferior to Paxlovid with respect to the time to sustained clinical recovery and with fewer safety concerns. This manuscript examines what is known about VV116 and explores how this novel treatment option may be used in the future to address the ongoing SARS-CoV-2 pandemic.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: ritonavir → Rx: ritonavir-100-mg → Rx: adenosine → Rx: nirmatrelvir-and-ritonavir → Condition: hiv-in-women → Condition: bacterial-infections →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 36932818: Phase III Randomized Trial: VV116 as a potential treatment for COVID-19

3 of 3 Free Questions Remaining